Access to Early Detection is a Critical Next Step in Alzheimer’s Care
Updated: Nov 10
By Penn Quarter Partners
Alzheimer’s is a major national health concern. One in every nine Americans age 65 and older has the disease, and one in three seniors dies of Alzheimer’s or another dementia. The mortality rate associated with Alzheimer’s and other dementias has doubled over the last quarter-century.
At the same time, the field is seeing significant developments, from disease-modifying therapies that can slow cognitive decline by targeting amyloid plaques in the brain to blood-based tests that can help detect Alzheimer’s disease in its early stages.
These minimally invasive early detection tests represent an important development in Alzheimer’s care. Early detection can give patients and their families more time to prepare for health care arrangements, caregiving needs, and financial considerations. A simple blood test can provide information that allows families to begin making those plans earlier.
Having those results also gives patients an opportunity to discuss them with their health care providers and learn more about available options for slowing disease progression.
Congress has the opportunity to make this testing more accessible to those at heightened risk for Alzheimer’s.
Although these new tests have been cleared by the Food and Drug Administration for use in diagnosing Alzheimer’s disease, Medicare coverage currently applies when they are used to evaluate patients with symptoms or other clinical indications. These new tests also have the potential to help detect Alzheimer’s disease before symptoms appear, but Medicare would not currently cover them when used for this purpose because they would be considered a preventive service. Under current law, new preventive care products and services generally cannot receive Medicare coverage until they receive a recommendation from the U.S. Preventive Services Task Force, a process that can take many years.
During that time, patients and families who could benefit from earlier detection may be left without access to information that could help them plan for the future or discuss treatment options with their health care providers.
Policy discussions are underway around how to expand access to early Alzheimer’s detection, including the bipartisan Alzheimer’s Screening and Prevention (ASAP) Act, which would create a pathway for future FDA-approved blood-based tests to be covered by Medicare for screening before symptoms appear. In September, the legislation advanced through the House Ways and Means Committee. The House Energy and Commerce Committee also held a legislative hearing on the measure. It has also garnered bipartisan support in both chambers, with a growing number of lawmakers cosponsoring the measure or expressing support for its provisions.
As Congress considers its legislative priorities for the remainder of the year, the ASAP Act remains one potential vehicle for addressing Medicare coverage of emerging Alzheimer’s detection technologies. Its consideration during November, Alzheimer’s Disease Awareness Month, would also bring additional attention to the role of early detection in Alzheimer’s care.
As Alzheimer’s diagnostics and treatments continue to advance, ensuring that patients can access new tools for early detection will be an important part of translating those advances into better care.


